IsoPlexis (IsoPlexis) Total Inventories : $27.52 Mil (As of Dec. 2022)

View and export this data going back to 2021. Start your Free Trial

What is IsoPlexis Total Inventories?

IsoPlexis's total inventories for the quarter that ended in Dec. 2022 was $27.52 Mil. IsoPlexis's average total inventories from the quarter that ended in Sep. 2022 to the quarter that ended in Dec. 2022 was $32.88 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. IsoPlexis's Net-Net Working Capital per share for the quarter that ended in Dec. 2022 was $-0.33.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. IsoPlexis's Days Inventory for the three months ended in Dec. 2022 was 268.50.

Inventory Turnover measures how fast the company turns over its inventory within a year. IsoPlexis's Inventory Turnover for the quarter that ended in Dec. 2022 was 0.34.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. IsoPlexis's Inventory-to-Revenue for the quarter that ended in Dec. 2022 was 9.78.

IsoPlexis Total Inventories Historical Data

The historical data trend for IsoPlexis's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IsoPlexis Total Inventories Chart

IsoPlexis Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Total Inventories

3.19

3.96

24.30

27.52

IsoPlexis Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Total Inventories	Get a 7-Day Free Trial								24.30	34.50	38.99	38.25	27.52

IsoPlexis Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

IsoPlexis (NAS:ISO) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

IsoPlexis's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2022 is

	Net-Net Working Capital Per Share (Q: Dec. 2022 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(37.465	+	0.75 * 4.502	+	0.5 * 27.516	-	67.801
-	0	-	0)	/	39.6712
=	-0.33

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

IsoPlexis's Days Inventory for the three months ended in Dec. 2022 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Dec. 2022 )	/	Cost of Goods Sold (Q: Dec. 2022 )	*	Days in Period
	=	32.8815	/	11.175	*	365 / 4
	=	268.50

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

IsoPlexis's Inventory Turnover for the quarter that ended in Dec. 2022 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Dec. 2022 )	/	Average Total Inventories (Q: Dec. 2022 )
	=	11.175	/	32.8815
	=	0.34

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

IsoPlexis's Inventory to Revenue for the quarter that ended in Dec. 2022 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Dec. 2022 )	/	Revenue (Q: Dec. 2022 )
	=	32.8815	/	3.361
	=	9.78

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

IsoPlexis Total Inventories Related Terms

Thank you for viewing the detailed overview of IsoPlexis's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

IsoPlexis (IsoPlexis) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » IsoPlexis Corp (NAS:ISO) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

N/A

Address

35 North East Industrial Road, Branford, CT, USA, 06405

Website

https://www.isoplexis.com

IsoPlexis Corp is a developer of a single-cell detection system designed to accelerate insights in the field of cancer. It designed a platform to reveal functional protein biology and cellular signaling networks at single-cell resolution to accelerate the development of advanced medicines.

Executives

Nachum Shamir	director	12212 TECHNOLOGY BLVD, AUSTIN TX 78727
John Strahley	officer: Chief Financial Officer	35 NORTH EAST INDUSTRIAL ROAD, BRANFORD CT 06405
Sean Mackay	director, officer: Chief Executive Officer	35 NORTH EAST INDUSTRIAL ROAD, BRANFORD CT 06405
Rew Richard W. Ii	officer: SVP, GC & Secretary	7000 WEST WILLIAM CANNON, BUILDING ONE, AUSTIN TX 78735
James R Heath	director	C/O ISOPLEXIS, 35 NE INDUSTRIAL RD, BRANFORD CT 06405
Michael Egholm	director	1 FRANKLIN STREET, UNIT 3104, BOSTON MA 02110
Siddhartha Kadia	director	7475 LUSK BOULEVARD, SAN DIEGO CA 92121
Jason W. Myers	director	C/O ARCHERDX, INC., 2477 55TH STREET, SUITE 202, BOULDER CO 80301
John G. Conley	director	396 GREAT MEADOWS RD, CONCORD MA 01742-1803
Gregory P. Ho	director, 10 percent owner	C/O SPRING MOUNTAIN CAPITAL, LP, 650 MADISON AVENUE, 20TH FLOOR, NEW YORK NY 10022
Peter Siesel	officer: Chief Commercial Officer	35 NORTH EAST INDUSTRIAL ROAD, BRANFORD CT 06405
Jing Zhou	officer: Chief Scientific Officer	35 NORTH EAST INDUSTRIAL ROAD, BRANFORD CT 06405
Rajesh T. Khakhar	officer: VP, Finance	35 NORTH INDUSTRIAL ROAD, BRANFORD CT 06405
Northpond Capital Gp, Llc	10 percent owner	4 BRATTLE STREET, FLOOR 3, CAMBRIDGE MA 02138
Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003